Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00405730 | Nepafenac 0.1% Eye Drops, Suspension Compared to Ketorolac Trometamol 0.5% Eye Drops, Solution and Placebo | PHASE3 | COMPLETED | 227 | — | — | Nov 1, 2005 | Jul 1, 2006 | Nov 18, 2016 | 1 | France |
Cure is defined as aqueous cells score = 0 and aqueous cells score = 0 at Day 14.
| Arm | Type | Description |
|---|---|---|
| Nepafenac | EXPERIMENTAL | One drop in the study eye 3 times daily for 23 days |
| Ketorolac Trometamol | ACTIVE_COMPARATOR | One drop in the study eye 3 times daily for 23 days |
| Nepafenac Vehicle | PLACEBO_COMPARATOR | One drop in the study eye 3 times daily for 23 days |
| Name | Type | Description |
|---|---|---|
| Nepafenac 1mg/ml eye drops, suspension | DRUG | One drop in the study eye 3 times daily for 23 days |
| Ketorolac Trometamol 5 mg/ml eye drops, solution | DRUG | One drop in the study eye 3 times daily for 23 days |
| Nepafenac vehicle eye drops | OTHER | One drop in the study eye 3 times daily for 23 days |
Inclusion Criteria: * Patients (18 years or older) of any race and either sex, requiring cataract extraction with planned implantation of a posterior chamber intraocular lens. * Other protocol-defined inclusion criteria may apply. Exclusion Criteria: * Under 18. * Other protocol-defined exclusion...